Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 80

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 80
---
, and Mr. Richmond would have been entitled to receive the following payments and benefits under the change in control agreements:

| ● | Mr. Michael: cash termination payments—$13,196,490; additional Supplemental Pension Plan benefits—$14,132,667; welfare and fringe benefits—$99,078. |

| ● | Mr. Gonzalez: cash termination payments—$16,779,631; additional Supplemental Pension Plan benefits—$0; welfare and fringe benefits—$53,317. |

| ● | Mr. Reents: cash termination payments—$7,354,553; additional Supplemental Pension Plan benefits—$5,857,009; welfare and fringe benefits—$78,386. |

| ● | Mr. Stewart: cash termination payments—$10,058,069; additional Supplemental Pension Plan benefits—$6,011,693; welfare and fringe benefits—$97,514. |

| ● | Dr. Saleki-Gerhardt: cash termination payments—$7,982,782; additional Supplemental Pension Plan benefits—$2,103,056; welfare and fringe benefits—$74,310. |

70 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

| ● | Mr. Richmond: cash termination payments—$7,833,282; additional Supplemental Pension Plan benefits—$3,252,837; welfare and fringe benefits—$96,538. |

Because the termination date is assumed to occur at the end of the 2024 performance period, the cash termination payments include an amount reflecting the excess, if any, of (a) the bonus entitlement under the change in control agreements, which would be based on the higher of target performance and the average bonus for the past three years, over (b) the actual bonus earned by the NEO for the 2024 performance period, as shown in the Summary Compensation Table in the column captioned “Non-Equity Incentive Plan Compensation.” EQUITY AWARDS The AbbVie Amended and Restated 2013 Incentive Stock Program was approved by AbbVie’s stockholders and covers approximately 17,000 participants, including a broad group of management and professional staff. The NEO award agreements under the AbbVie Amended and Restated 2013 Incentive Stock Program provide that the award may be assumed, converted or replaced on an equivalent basis by the surviving company upon a change in control.